1
|
Bustamante J, Tran T, Rodriguez CR. Otitides: Acute and Chronic Otitis Media and Externa. Prim Care 2025; 52:1-14. [PMID: 39939081 DOI: 10.1016/j.pop.2024.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2025]
Abstract
Otitis media and otitis externa are common ear conditions affecting individuals of all ages. Symptoms can range from mild to severe ear pain. These conditions result from infections, immune responses, and environmental factors. Proper management requires use of up-to-date guidelines and advanced treatments to address the diagnosis, prevention, and therapy challenges. This article overviews current practices and recent developments in treating these common ear disorders.
Collapse
Affiliation(s)
- Jennifer Bustamante
- NSUKPCOM Family Medicine Residency Program, Evara Health; Department of Family Medicine, Evara Health, 14100 58 Street N, Clearwater, FL 33760, USA.
| | - Tony Tran
- PGY1, Department of Family Medicine, Evara Health, Clearwater, FL, USA
| | - Carlos R Rodriguez
- NSUKPCOM Family Medicine Residency Program, Evara Health; Department of Family Medicine, Evara Health, 14100 58 Street N, Clearwater, FL 33760, USA
| |
Collapse
|
2
|
Lin TY, Chiu CH, Woo PCY, Razak Muttalif A, Dhar R, Choon Kit L, Morales G, Ozbilgili E. Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012-2024. Hum Vaccin Immunother 2024; 20:2417554. [PMID: 39478351 PMCID: PMC11533800 DOI: 10.1080/21645515.2024.2417554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Revised: 09/30/2024] [Accepted: 10/14/2024] [Indexed: 11/06/2024] Open
Abstract
This narrative review describes pneumococcal serotype prevalence for invasive disease and carriage and antibiotic resistance among specimens collected from children in countries across South and Southeast Asia from 2012 to 2024. Literature search retrieved 326 articles; 96 were included. The prevalence of pneumococcal serotypes varied geographically and over time after introduction of pneumococcal conjugate vaccine. Serotypes common in both pneumococcal carriage and disease were 6A, 6B, 14, 15B/15C, 19F, and 23F; serotypes 1, 3, 5, 19A, 15A, 10A, and 35B were also common in disease. Most of these serotypes are included in the 13-valent and 10-valent PCV. Carriage and disease isolates remained generally highly susceptible to vancomycin (mostly 100%) and levofloxacin (mostly >97%). These findings indicate that vaccine-preventable serotypes contribute significantly to pneumococcal disease burden in children in South and Southeast Asia. Consistency of national immunization programs with World Health Organization recommendations may reduce rates of pneumococcal disease in this region.
Collapse
Affiliation(s)
- Tzou-Yien Lin
- Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Cheng-Hsun Chiu
- Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Patrick CY Woo
- Department of Microbiology, University of Hong Kong, Hong Kong, China
| | - Abdul Razak Muttalif
- Department of Medicine, Faculty of Medicine, MAHSA University, Jenjarom, Selangor, Malaysia
| | - Raja Dhar
- Department of Pulmonology, Calcutta Medical Research Institute, Kolkata, India
| | - Leong Choon Kit
- Tampines Family Medicine Clinic, Mission Medical Clinic, Hougang, Singapore
| | - Graciela Morales
- Emerging Markets Medical Affairs, Vaccines, Pfizer Inc, San Jose, Costa Rica
| | - Egemen Ozbilgili
- Emerging Markets Medical Affairs, Vaccines, Pfizer Pte Ltd., Singapore, Singapore
| |
Collapse
|
3
|
Rajam G, Hicks KL, Antonello JM, Zhang Y, Irey S, Kelly J, Cooper S, Rubinstein LJ. A novel immuno-molecular strategy for the detection of Streptococcus pneumoniae serotypes in human cerebrospinal and middle ear fluids. J Immunol Methods 2023:113516. [PMID: 37348647 DOI: 10.1016/j.jim.2023.113516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 06/13/2023] [Accepted: 06/16/2023] [Indexed: 06/24/2023]
Abstract
Streptococcus pneumoniae is one of the most common microorganisms causing acute otitis media (AOM) in children. While bacterial culture of middle ear fluid (MEF) is the gold standard to detect the etiological organisms, several host and pathogen factors impact the survival of the organisms resulting in false negatives. To overcome this limitation, we have developed and validated an innovative multiplex immuno-molecular assay to screen and detect the S. pneumoniae 15-valent pneumococcal conjugate vaccine (PCV15; STs 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) vaccine serotypes in MEF. This novel in vitro approach involves two-step testing. First, the MEF specimens were tested for highly conserved pneumococcal genes, autolysin, lytA, and pneumolysin, ply using direct PCR to identify pneumococcus positive specimens. The pneumococcus positive specimens were screened for the presence of vaccine serotype specific pneumococcal polysaccharides using a 15-plex Pneumococcal Antigen Detection (PAD) assay, with specific capture and detection monoclonal antibodies. Due to the lack of availability of MEF samples, cerebrospinal fluid (CSF) was used as the surrogate matrix for the development and validation of the PCR-PAD assays. The PCR and PAD assays were separately evaluated for sensitivity and specificity. Subsequently, the PCR-PAD assays were cross-validated with human MEF samples (n = 39) which were culture confirmed to contain relevant bacterial strains. The combined PCR-PAD assays demonstrated high rate of agreement 94.9% (95% CI; 82.7, 99.4%) with historical Quellung serotype data of these MEF samples. This novel PCR-PAD assay demonstrates the feasibility of combining molecular and immunological assays to screen and identify PCV15 pneumococcal vaccine serotypes in AOM clinical samples.
Collapse
|
4
|
Safari D, Wahyono DJ, Tafroji W, Darmawan AB, Winarti Y, Kusdaryanto WD, Paramaiswari WT, Pramono H, Pratiwi M, Chamadi MR. Serotype Distribution and Antimicrobial Resistance Profile of Haemophilus influenzae Isolated from School Children with Acute Otitis Media. Int J Microbiol 2022; 2022:5391291. [PMID: 35655653 PMCID: PMC9152372 DOI: 10.1155/2022/5391291] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2021] [Revised: 11/02/2021] [Accepted: 05/06/2022] [Indexed: 11/17/2022] Open
Abstract
Haemophilus influenzae is a Gram-negative opportunistic bacterial pathogen of the human respiratory tract. This study describes the prevalence, serotype distribution, and susceptibility profiles of H. influenzae strains isolated from the nasopharynx of school children with acute otitis media (AOM) in Banyumas Regency, Central Java, Indonesia. H. influenzae was isolated from nasopharyngeal swab specimens using chocolate agar plates supplemented with IsoVitaleX and bacitracin. Serotyping was performed using quantitative polymerase chain reaction. Antimicrobial susceptibility profiles were determined using a microdilution broth assay. H. influenzae was present in 69.7% of samples (85/122). Nontypeable H. influenzae (NHTi) was the most common serotype (95.3%), followed by H. influenzae type b (3.5%) and H. influenzae type f (1.2%). All the H. influenzae isolates were susceptible to levofloxacin, ceftriaxone, imipenem, meropenem, cefuroxime, and cefixime. Most isolates were susceptible to sparfloxacin (99%), cefepime (99%), amoxicillin/clavulanic acid 2 : 1 (99%), ampicillin/sulbactam 2 : 1 (96%), chloramphenicol (94%), tetracycline (93%), ampicillin (87%), and clarithromycin (82%). Nineteen percent of the isolates were resistant to cotrimoxazole, and 11% of the isolates were resistant to ampicillin. This study showed that H. influenzae carriage among samples was dominated by NTHi and less susceptible to cotrimoxazole.
Collapse
Affiliation(s)
- Dodi Safari
- Eijkman Institute for Molecular Biology/Pusat Riset Biologi Molekuler Eijkman, Cibinong, West Java, Indonesia
| | | | - Wisnu Tafroji
- Eijkman Institute for Molecular Biology/Pusat Riset Biologi Molekuler Eijkman, Cibinong, West Java, Indonesia
| | - Anton Budhi Darmawan
- Department of Otorhinolaryngology, Head and Neck Surgery, Jenderal Soedirman University, Purwokerto, Indonesia
| | - Yayah Winarti
- Eijkman Institute for Molecular Biology/Pusat Riset Biologi Molekuler Eijkman, Cibinong, West Java, Indonesia
| | - Wahyu Dwi Kusdaryanto
- Department of Otorhinolaryngology, Head and Neck Surgery, Jenderal Soedirman University, Purwokerto, Indonesia
| | | | | | - Meyta Pratiwi
- Jenderal Soedirman University, Purwokerto, Indonesia
| | | |
Collapse
|
5
|
Taylor SL, Papanicolas LE, Richards A, Ababor F, Kang WX, Choo JM, Woods C, Wesselingh SL, Ooi EH, MacFarlane P, Rogers GB. Ear microbiota and middle ear disease: a longitudinal pilot study of Aboriginal children in a remote south Australian setting. BMC Microbiol 2022; 22:24. [PMID: 35026986 PMCID: PMC8756658 DOI: 10.1186/s12866-022-02436-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Accepted: 12/29/2021] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Otitis media (OM) is a major disease burden in Australian Aboriginal children, contributing to serious long-term health outcomes. We report a pilot analysis of OM in children attending an outreach ear and hearing clinic in a remote south Australian community over a two-year period. Our study focuses on longitudinal relationships between ear canal microbiota characteristics with nasopharyngeal microbiota, and clinical and treatment variables. RESULTS Middle ear health status were assessed in 19 children (aged 3 months to 8 years) presenting in remote western South Australia and medical interventions were recorded. Over the two-year study period, chronic suppurative OM was diagnosed at least once in 7 children (37%), acute OM with perforation in 4 children (21%), OM with effusion in 11 children (58%), while only 1 child had no ear disease. Microbiota analysis of 19 children (51 sets of left and right ear canal swabs and nasopharyngeal swabs) revealed a core group of bacterial taxa that included Corynebacterium, Alloiococcus, Staphylococcus, Haemophilus, Turicella, Streptococcus, and Pseudomonas. Within-subject microbiota similarity (between ears) was significantly greater than inter-subject similarity, regardless of differences in ear disease (p = 0.0006). Longitudinal analysis revealed changes in diagnosis to be associated with more pronounced changes in microbiota characteristics, irrespective of time interval. Ear microbiota characteristics differed significantly according to diagnosis (P (perm) = 0.0001). Diagnoses featuring inflammation with tympanic membrane perforation clustering separately to those in which the tympanic membrane was intact, and characterised by increased Proteobacteria, particularly Haemophilus influenzae, Moraxella catarrhalis, and Oligella. While nasopharyngeal microbiota differed significantly in composition to ear microbiota (P (perm) = 0.0001), inter-site similarity was significantly greater in subjects with perforated tympanic membranes, a relationship that was associated with the relative abundance of H. influenzae in ear samples (rs = - 0.71, p = 0.0003). Longitudinal changes in ear microbiology reflected changes in clinical signs and treatment. CONCLUSIONS Children attending the ear and hearing clinic in a remote Aboriginal community present with a broad spectrum of OM conditions and severities, consistent with other remote Aboriginal communities. Ear microbiota characteristics align with OM diagnosis and change with disease course. Nasopharyngeal microbiota characteristics are consistent with the contribution of acute upper respiratory infection to OM aetiology.
Collapse
Affiliation(s)
- Steven L Taylor
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
| | - Lito E Papanicolas
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| | - Alyson Richards
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Furdosa Ababor
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Wan Xian Kang
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Jocelyn M Choo
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| | - Charmaine Woods
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
- Department of Otolaryngology, Head & Neck Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia
| | - Steve L Wesselingh
- South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Eng H Ooi
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
- Department of Otolaryngology, Head & Neck Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia
| | - Patricia MacFarlane
- Department of Otolaryngology, Head & Neck Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia
| | - Geraint B Rogers
- Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| |
Collapse
|
6
|
Ura B, Celsi F, Zupin L, Arrigoni G, Battisti I, Gaita B, Grasso DL, Orzan E, Sagredini R, Barbi E, Crovella S. Proteomic Study Identifies Glycolytic and Inflammation Pathways Involved in Recurrent Otitis Media. Int J Mol Sci 2020; 21:ijms21239291. [PMID: 33291465 PMCID: PMC7731350 DOI: 10.3390/ijms21239291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 11/24/2020] [Accepted: 12/01/2020] [Indexed: 12/21/2022] Open
Abstract
Recurrent acute otitis media (RAOM) in children is clinically defined as the occurrence of at least three episodes of acute otitis media over a course of 6 months. A further common pathological condition of interest in the context of pediatric otolaryngology is adenotonsillar hypertrophy (ATH), a common cause of obstructive sleep apnea syndrome. Aimed at unraveling the differential modulation of proteins in the two pathologies and at understanding the possible pathways involved in their onset, we analyzed the proteomic profile of the adenoids from 14 RAOM and ATH patients by using two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS). The 2-DE coupled with MS allowed us to identify 23 spots with significant (p-value < 0.05) changes in protein amount, recognizing proteins involved in neutrophil degranulation and glycolysis pathways.
Collapse
Affiliation(s)
- Blendi Ura
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Fulvio Celsi
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
- Correspondence: ; Tel.: +39-390403785216
| | - Luisa Zupin
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Giorgio Arrigoni
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.A.); (I.B.)
- Proteomics Center, University of Padova and Azienda Ospedaliera di Padova, Via G. Orus 2/B, 35129 Padova, Italy
- CRIBI Biotechnology Center, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy
| | - Ilaria Battisti
- Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, 35121 Padova, Italy; (G.A.); (I.B.)
- Proteomics Center, University of Padova and Azienda Ospedaliera di Padova, Via G. Orus 2/B, 35129 Padova, Italy
| | - Bartolomea Gaita
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Domenico Leonardo Grasso
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Eva Orzan
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Raffaella Sagredini
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
| | - Egidio Barbi
- Institute for Maternal and Child Health–IRCCS “Burlo Garofolo”, 65/1 Via dell’Istria, 34137 Trieste, Italy; (B.U.); (L.Z.); (B.G.); (D.L.G.); (E.O.); (R.S.); (E.B.)
- Department of Medical, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy
| | - Sergio Crovella
- Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University—Women′s College of Sciences Building, Doha 2713, Qatar;
| |
Collapse
|
7
|
Jalali MM, Nezamdoust F, Ramezani H, Pastadast M. Prevalence of Hearing Loss among School-Age Children in the North of Iran. IRANIAN JOURNAL OF OTORHINOLARYNGOLOGY 2020; 32:85-92. [PMID: 32219074 PMCID: PMC7085924 DOI: 10.22038/ijorl.2019.36090.2191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Introduction: The present study aimed to investigate the audiological profiles of elementary school-age children in Rasht, Iran, and estimate the prevalence of hearing impairments in this population. Materials and Methods: In this cross-sectional descriptive-analytical study, the hearing threshold was screened using pure tone audiometry (PTA). Hearing impairment was defined as equal to or higher than 20 dB HL. Results of the hearing thresholds were separately reported in the left or right ears and better or worse ears. Logistic regression tests were used to investigate the association between hearing loss and possible risk factors. In this study, all the analyses were conducted using SPSS software (version 21). Results: The present study was carried out on a total of 2019 children. Mean age of the participants was reported as 9.66±1.66 years. Based on low-frequency pure-tone average, the prevalence rates of hearing loss > 15 dB in the right and left ears were reported as 1.94% and 1.68%, respectively. The high-frequency hearing loss > 15 dB in the right and left ears was obtained at 1.14% and 1.04%, respectively. Prevalence rate of hearing loss (in all frequencies) in boys was higher than that in girls. There was a strong association between a history of otitis media and sensorineural or conductive hearing loss (adjusted odds ratio reported as 12.2 and 8.1, respectively). Conclusion: In this study, the rate of hearing loss in the participants was approximately 2%. It was concluded that the screening of hearing loss in children is necessary for the identification and management of these children as early as possible. It is recommended to perform further trials to investigate the impact of different causes on childhood hearing impairment.
Collapse
Affiliation(s)
- Mir Mohammad Jalali
- Otorhinolaryngology Research Center, Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Fatemeh Nezamdoust
- Otorhinolaryngology Research Center, Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Hedieh Ramezani
- Otorhinolaryngology Research Center, Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Masomeh Pastadast
- Otorhinolaryngology Research Center, Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| |
Collapse
|
8
|
Mather MW, Drinnan M, Perry JD, Powell S, Wilson JA, Powell J. A systematic review and meta-analysis of antimicrobial resistance in paediatric acute otitis media. Int J Pediatr Otorhinolaryngol 2019; 123:102-109. [PMID: 31085462 DOI: 10.1016/j.ijporl.2019.04.041] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 03/16/2019] [Accepted: 04/30/2019] [Indexed: 12/18/2022]
Abstract
OBJECTIVE OF REVIEW Acute otitis media (AOM) is the largest cause of antimicrobial prescriptions amongst children in developed countries. Excessive and inappropriate prescribing is known to drive antimicrobial resistance, but less is known of antimicrobial resistance in AOM-associated bacteria. TYPE OF REVIEW & SEARCH STRATEGY We conducted a systematic review and meta-analysis of bacterial prevalence and antimicrobial resistance in studies of paediatric AOM identified from Ovid Medline, Embase and the Cochrane library. RESULTS From 48 unique studies, 15,871 samples were included. Only 0.67 (CI 0.63-0.71) of all ear samples grew a bacterial pathogen. The most common bacterial causes of AOM in children were Streptococcus pneumoniae 0.30 (CI 0.27-0.32), Haemophilus influenza 0.23 (CI 0.20-0.26), and Moraxella catarrhalis 0.05 (CI 0.04-0.06). Resistance patterns varied amongst organisms and antimicrobial agents. The pooled proportion of bacterial culture-positive episodes of AOM that could be effectively treated with amoxicillin was 0.85 (CI 0.76-0.94), erythromycin was 0.64 (0.48-0.78) and amoxicillin-clavulanate was 0.95 (CI 0.85-0.98). CONCLUSION We have demonstrated the bacteriology and antimicrobial resistance patterns of AOM. Of samples which grew bacteria, on average approximately 15% of isolates demonstrated resistance to amoxicillin; a typical first-line agent. Greater understanding of local bacteriology and resistance patterns is needed to enable improved antimicrobial stewardship.
Collapse
Affiliation(s)
- Michael W Mather
- Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK; Department of Otolaryngology, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK
| | - Michael Drinnan
- Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK
| | - John D Perry
- Department of Microbiology, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK
| | - Steven Powell
- Department of Otolaryngology, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK
| | - Janet A Wilson
- Department of Otolaryngology, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK; Institute of Health and Society, Newcastle University, Richardson Road, Newcastle Upon Tyne, NE2 4AX, UK
| | - Jason Powell
- Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK; Department of Otolaryngology, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK.
| |
Collapse
|
9
|
Van Dyke MK, Pirçon JY, Cohen R, Madhi SA, Rosenblüt A, Macias Parra M, Al-Mazrou K, Grevers G, Lopez P, Naranjo L, Pumarola F, Sonsuwan N, Hausdorff WP. Etiology of Acute Otitis Media in Children Less Than 5 Years of Age: A Pooled Analysis of 10 Similarly Designed Observational Studies. Pediatr Infect Dis J 2017; 36:274-281. [PMID: 27918383 PMCID: PMC5312727 DOI: 10.1097/inf.0000000000001420] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/27/2016] [Indexed: 11/26/2022]
Abstract
BACKGROUND Acute otitis media (AOM) is an important cause of childhood morbidity and antibiotic prescriptions. However, the relative importance of the well-known otopathogens, Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hflu), remains unclear because of a limited number of tympanocentesis-based studies that vary significantly in populations sampled, case definitions and heptavalent pneumococcal conjugate vaccine use. METHODS We conducted a pooled analysis of results from 10 AOM etiology studies of similar design, the protocols of which were derived from a common protocol and conducted in children 3 months to 5 years of age in different countries. Generalized estimating equations were used to account for within-study correlations. RESULTS The majority, 55.5% (95% confidence interval: 47.0%-65.7%) of 1124 AOM episodes, were bacterial pathogen positive: 29.1% (24.8%-34.1%) yielded Hflu and 23.6% (19.0%-29.2%) Spn. Proportions of Hflu and Spn were higher and lower, respectively, in heptavalent pneumococcal conjugate vaccine-vaccinated children. Hflu and Spn were each isolated from 20% to 35% of children in every 1-year age range. Hflu was less likely to be isolated from first (vs. subsequent) episodes [relative risk (RR): 0.71 (0.60-0.84)]. Spn was more often isolated from sporadic (vs. recurrent) cases [RR: 0.76 (0.61-0.97)]; the opposite was true for Hflu [RR: 1.4 (1.00-1.96)]. Spn cases were more likely to present with severe (vs. mild) symptoms [RR: 1.42 (1.01-2.01)] and Hflu cases with severe tympanic membrane inflammation [RR: 1.35 (1.06-1.71)]. CONCLUSIONS Spn and Hflu remain the leading otopathogens in all populations examined. While associated with overlapping symptoms and severity, they exhibit some differences in their likelihood to cause disease in specific subpopulations.
Collapse
Affiliation(s)
- Melissa K. Van Dyke
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Jean-Yves Pirçon
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Robert Cohen
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Shabir A. Madhi
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Andrés Rosenblüt
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Mercedes Macias Parra
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Khalid Al-Mazrou
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Gerhard Grevers
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Pio Lopez
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Laura Naranjo
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Felix Pumarola
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - Nuntigar Sonsuwan
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| | - William P. Hausdorff
- From the GSK Vaccines, Wavre, Belgium; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, CHI Créteil and UPEC, France; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Unidad de Otorrinolaringologia, Hospital Dr Sotero del Rio, Puente Alto, Santiago, Chile; Departamento de Infectologia, Instituto Nacional de Pediatría de la Secretaría de Salud (SSA), Mexico City, Mexico; Otolaryngology Department, King Saud University & King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; ENT-Center, Prinzenweg 1, 82319 Starnberg, Germany; Centros de Estudios Infectologia Pediatrica, Cali, Colombia; GSK Biologicals, Ciudad Panama, Panama; Sección de ORL Pediátrica, Hospital Universitari Vall d’Hebron, Barcelona, Spain; and Otolaryngology Department, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand
| |
Collapse
|
10
|
Rosenblut A, Napolitano C, Pereira A, Moreno C, Kolhe D, Lepetic A, Ortega-Barria E. Etiology of acute otitis media and serotype distribution of Streptococcus pneumoniae and Haemophilus influenzae in Chilean children <5 years of age. Medicine (Baltimore) 2017; 96:e5974. [PMID: 28178138 PMCID: PMC5312995 DOI: 10.1097/md.0000000000005974] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 12/19/2016] [Accepted: 01/02/2017] [Indexed: 11/26/2022] Open
Abstract
The impact of bacterial conjugate vaccines on acute otitis media (AOM) is affected by several factors including population characteristics, bacterial etiology and vaccine conjugation method, carrier, and coverage. This study estimated the baseline etiology, distribution, and antibiotic susceptibility of bacterial serotypes that causes AOM in children aged <5 years in a public setting in Santiago, Chile.Children aged ≥3 months and <5 years referred to the physician for treatment of AOM episodes (with an onset of symptoms <72 h) were enrolled between September 2009 and September 2010. Middle ear fluid (MEF) was collected by tympanocentesis or by otorrhea for identification and serotyping of bacteria. Antibacterial susceptibility was tested using E-test (etrack: 112671).Of 160 children (mean age 27.10 ± 15.83 months) with AOM episodes, 164 MEF samples (1 episode each from 156 children; 2 episodes each from 4 children) were collected. Nearly 30% of AOM episodes occurred in children aged 12 to 23 months. Streptococcus pneumoniae (41.7% [58/139]) and Haemophilus influenzae (40.3% [56/139]) were predominant among the cultures that showed bacterial growth (85% [139/164]). All Streptococcus pneumoniae positive episodes were serotyped, 19F (21%) and 14 (17%) were the predominant serotypes; all Haemophilus influenzae strains were nontypeable. Streptococcus pneumoniae were resistant to penicillin (5%) and erythromycin (33%); Haemophilus influenzae were resistant to ampicillin (14%) and cefuroxime and cefotaxime (2% each).AOM in Chilean children is predominantly caused by Streptococcus pneumoniae and nontypeable Haemophilus influenzae. Use of a broad spectrum vaccine against these pathogens might aid the reduction of AOM in Chile.
Collapse
Affiliation(s)
- Andres Rosenblut
- Unidad de Otorrinolaringología, Hospital Sótero del Rio, Puente Alto, Santiago, Chile
| | - Carla Napolitano
- Unidad de Otorrinolaringología, Hospital Sótero del Rio, Puente Alto, Santiago, Chile
| | - Angelica Pereira
- Unidad de Otorrinolaringología, Hospital Sótero del Rio, Puente Alto, Santiago, Chile
| | - Camilo Moreno
- Merck & Co, Sao Paulo, Brazil; at the time of the study Takeda Pharmaceuticals, Sao Paulo, Brazil
| | | | | | | |
Collapse
|
11
|
Chen Z, Guo R, Xu J, Qiu C. Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier. Front Med 2016; 10:490-498. [PMID: 27650380 DOI: 10.1007/s11684-016-0470-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 07/05/2016] [Indexed: 12/28/2022]
Abstract
This study evaluated the immunogenicity and protective immunity of a Hemophilus influenzae b (Hib) polysaccharide conjugate vaccine with the pneumococcal surface adhesin A (PsaA) protein carrier in young mice. The Hib polysaccharide was conjugated with the rPsaA protein carrier, which was produced using recombinant DNA technology. A total of 15 young mice aged 3 weeks to 5 weeks were immunized with the conjugate vaccine, and another 15 young mice of the same age were immunized with the licensed Hib-tetanus toxoid (TT) vaccine. Furthermore, the third group of 15 young mice was inoculated with phosphate buffer saline as control. The immunized mice were inoculated with pneumococcus in the middle ear. Results showed that IgG antibody responses against both the PsaA protein and Hib polysaccharide were observed in the Hib-PsaA group. However, no statistical difference was observed in the titer of IgG against the Hib polysaccharide between Hib-PsaA and Hib-TT groups. The elimination rate of pneumococcus and the inflammation of the middle ear showed the effectiveness of protective immunity against otitis media caused by pneumococcus. Our results suggest that the Hib polysaccharide can be successfully conjugated with rPsaA via amide condensation. This new Hib-PsaA conjugate vaccine can induce both anti-PsaA and anti-Hib immune responses in young mice and elicit effective protection against acute otitis media caused by pneumococcus.
Collapse
Affiliation(s)
- Zeyu Chen
- Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
- Shanghai Clinical Medical Center of Hearing Medicine, Shanghai, 200031, China.
| | - Rong Guo
- The Laboratory of Bacterial Vaccine, Wuhan Institute of Biological Products, Wuhan, 430207, China
| | - Jianghong Xu
- Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China
- Shanghai Clinical Medical Center of Hearing Medicine, Shanghai, 200031, China
| | - Chuangjun Qiu
- Dingtai-Haigui Biotechnology Co. Ltd., Gu'an, 065500, China
| |
Collapse
|
12
|
Sonsuwan N, Watcharinyanon P, Sawanyawisuth K. What are the leading causative pathogens in acute otitis media with tympanic membrane perforation? Int J Pediatr Otorhinolaryngol 2016; 90:20-22. [PMID: 27729132 DOI: 10.1016/j.ijporl.2016.08.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 08/25/2016] [Accepted: 08/25/2016] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Acute otitis media (AOM) is a common infectious disease in children. Data regarding the distribution of causative pathogens are not universal. Tympanic perforation due to AOM may occur in 5-30% of AOM patients. The causative pathogens for AOM with tympanic perforation are limited. METHODS This was a prospective study conducted at the Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Thailand. All consecutive children diagnosed as having AOM with tympanic perforation were enrolled. The age of the eligible patients was between 3 months and 5 years. Pus from the middle ear of each patient was swabbed and tested for culture/sensitivity. RESULTS There were 40 eligible patients diagnosed with AOM with tympanic perforation in this study. The mean age of all patients was 24.3 months and the patients were predominantly male (26 male; 65.0%). None of these patients received S. pneumoniae or H. influenzae vaccination. All specimens were culture positive (100%) and 13 organisms were identified. There were 53 identified pathogens; the most common pathogen was H. influenzae (19 times or 35.8%), followed by Staphylococcus aureus (14 times or 26.4%). H. influenzae was 100% sensitive to chloramphenicol, amoxicilllin/clavulanic acid, cefotaxime, and ciprofloxacin, while S. aureus was also 100% sensitive to oxacillin, vancomycin, and fusidic acid. CONCLUSIONS The two most common pathogens for AOM with tympanic perforation were H. influenzae and Staphylococcus aureus. Both pathogens were mostly sensitive to antibiotics.
Collapse
Affiliation(s)
- Nuntigar Sonsuwan
- Department of Otolaryngology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
| | | | - Kittisak Sawanyawisuth
- Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand; Research Center in Back, Neck Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen 40002, Thailand; Internal Medicine Research Group, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
| |
Collapse
|
13
|
Ngo CC, Massa HM, Thornton RB, Cripps AW. Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. PLoS One 2016; 11:e0150949. [PMID: 26953891 PMCID: PMC4783106 DOI: 10.1371/journal.pone.0150949] [Citation(s) in RCA: 162] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2015] [Accepted: 02/22/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Otitis media (OM) is amongst the most common childhood diseases and is associated with multiple microbial pathogens within the middle ear. Global and temporal monitoring of predominant bacterial pathogens is important to inform new treatment strategies, vaccine development and to monitor the impact of vaccine implementation to improve progress toward global OM prevention. METHODS A systematic review of published reports of microbiology of acute otitis media (AOM) and otitis media with effusion (OME) from January, 1970 to August 2014, was performed using PubMed databases. RESULTS This review confirmed that Streptococcus pneumoniae and Haemophilus influenzae, remain the predominant bacterial pathogens, with S. pneumoniae the predominant bacterium in the majority reports from AOM patients. In contrast, H. influenzae was the predominant bacterium for patients experiencing chronic OME, recurrent AOM and AOM with treatment failure. This result was consistent, even where improved detection sensitivity from the use of polymerase chain reaction (PCR) rather than bacterial culture was conducted. On average, PCR analyses increased the frequency of detection of S. pneumoniae and H. influenzae 3.2 fold compared to culture, whilst Moraxella catarrhalis was 4.5 times more frequently identified by PCR. Molecular methods can also improve monitoring of regional changes in the serotypes and identification frequency of S. pneumoniae and H. influenzae over time or after vaccine implementation, such as after introduction of the 7-valent pneumococcal conjugate vaccine. CONCLUSIONS Globally, S. pneumoniae and H. influenzae remain the predominant otopathogens associated with OM as identified through bacterial culture; however, molecular methods continue to improve the frequency and accuracy of detection of individual serotypes. Ongoing monitoring with appropriate detection methods for OM pathogens can support development of improved vaccines to provide protection from the complex combination of otopathogens within the middle ear, ultimately aiming to reduce the risk of chronic and recurrent OM in vulnerable populations.
Collapse
Affiliation(s)
- Chinh C. Ngo
- School of Medical Science, Griffith University, Gold Coast, Queensland, Australia
- Molecular Basis of Disease, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
| | - Helen M. Massa
- School of Medical Science, Griffith University, Gold Coast, Queensland, Australia
- Molecular Basis of Disease, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- * E-mail:
| | - Ruth B. Thornton
- School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia
- Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
| | - Allan W. Cripps
- School of Medical Science, Griffith University, Gold Coast, Queensland, Australia
- Molecular Basis of Disease, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
| |
Collapse
|
14
|
Zielnik-Jurkiewicz B, Bielicka A. Antibiotic resistance of Streptococcus pneumoniae in children with acute otitis media treatment failure. Int J Pediatr Otorhinolaryngol 2015; 79:2129-33. [PMID: 26454530 DOI: 10.1016/j.ijporl.2015.09.030] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 09/22/2015] [Accepted: 09/23/2015] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The emergence of antibiotic-resistant bacteria is a major cause of treatment failure in children with acute otitis media (AOM). This study aimed to analyze the types of bacterial strains in fluid isolated from the middle ear of children with AOM who did not respond to oral antibiotic treatment. We also determined the antibiotic resistance of the most frequently isolated bacterial strain (Streptococcus pneumoniae) found in these children. METHODS This was a prospective study of 157 children with AOM aged from 6 months to 7 years admitted due to unsuccessful oral antibiotic treatment. All children underwent a myringotomy, and samples of the middle ear fluid were collected for bacteriological examination. RESULTS Positive bacterial cultures were obtained in 104 patients (66.2%), with Streptococcus pneumoniae (39.69%), Haemophilus influenzae (16.03%) Staphylococcus aureus (16.03%), Staphylococcus haemolyticus (6.9%) and Streptococcus pyogenes (5.34%) found most frequently. The majority (65.4%) of S. pneumoniae strains were penicillin-intermediate-resistant or penicillin-resistant, and 67.2% strains of S. pneumoniae were multidrug-resistant. CONCLUSIONS We identified S. pneumoniae as the most frequently isolated pathogen from the middle ear in children with AOM treatment failure and determined that the majority of strains were antibiotic-resistant. We propose that the microbiological identification of bacterial strains and their degree of antibiotic resistance should be performed prior to therapy in order to choose the most appropriate antibiotic therapy for children with AOM treatment failure.
Collapse
Affiliation(s)
| | - Anna Bielicka
- ENT Department, Children's Hospital, 4/24 Niekłańska Str. 03-924 Warsaw, Poland
| |
Collapse
|